Company intelligence / Profile preview

Fusionbio Pharma

Not specified, Not specified, United Statesfusionpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

FusionBio develops novel protein-based therapies using a proprietary technology to generate stable trimeric ligands targeting immune-mediated diseases such as cancer and autoimmunity. The approach aims to enhance immunotherapy efficacy without introducing external immunogenicity issues. No published clinical results or advanced-stage programs were identified.

Therapeutic areas: OncologyImmunology
Modalities: Protein therapeutics (stable covalent trimers of tumor necrosis factor superfamily ligands)
Industry: Biotech

Drug pipeline

1 asset

FPI-2265

Phase 2

Indications: Metastatic castration-resistant prostate cancer

Partnerships

Not specified/publicly disclosed

Beyond the preview

Go deeper on Fusionbio Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fusionbio Pharma.

Explore the full profile